Quince Therapeutics, INC 8-K filings
NASDAQ
8-K: Quince Therapeutics Stockholders Approve Reverse Stock Split and Elect Directors at Annual Meeting
Quince Therapeutics held its annual meeting on June 5, 2024, where stockholders approved a reverse stock split, elected three directors, ratified the accounting firm, and approved executive compensation on an advisory basis.
NASDAQ
Quince Therapeutics has appointed Rajiv Patni to its board of directors, effective February 15, 2024, with compensation including an annual retainer and stock options.
NASDAQ
Quince Therapeutics' executive officers will not receive salary increases in 2024, but have been granted stock options.